Find a Clinical Trial

Showing 1 - 10 of 21 Trials
  • Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of an investigational drug called ALN-BCAT, and find out what effects, if any, ALN-BCAT has on people with your type of liver cancer. The effects being studied include: • The frequency and severity of side effects (to determine if the drug is safe) • Whether ALN-BCAT may make tumors smaller • How ALN-BCAT may affect the genes and proteins in your cancer cells • How your body processes ALN-BCAT Are you Eligible? (Inclusion Criteria) Age 18 years or older - Patient able to understand and willing and able to comply with...
  • Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    NA
    That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC...
  • Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of a drug called ZEN003694 (ZEN-3694), in combination with the usual approach of capecitabine. This study tests different doses of ZEN003694 in combination with capecitabine to see which dose is safer for people. There will be between 21 and 30 people taking part in this study. This drug combination is not approved by the FDA for treatment of the disease being studied. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Have you been diagnosed with metastatic or unresectable cancer, which progressed while you were treated...
  • Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not “on the market” (available for you to receive a prescription for and/or to buy) in any country. In this study, different dose levels of IDE397 will be tested. About 40 patients are expected to participate at approximately 6-8 study centers within the US. At a minimum, 2 patients will be enrolled in each dose level. There will be about 10 dose levels tested (starting at 5 mg). Every time a dose level is found to be safe, a...
  • Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans. Are you Eligible...
  • Principal Investigator:

    Benjamin Herzberg, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This research study is being done to test the safety of an investigational treatment called LY4066434 when given alone or with other cancer drugs. LY4066434 is an investigational (or experimental) drug, taken orally. It was designed for patients that have abnormalities (also known as DNA mutations) in the KRAS gene that can occur in some types of cancer. LY4066434 is not approved by the U.S. Food and Drug Administration. Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age, 2. Must be able to swallow tablets. 3. Must be able to comply with outpatient treatment, laboratory...
  • Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to test the safety of the experimental drugs called 68Ga-FAP-2286 and 177Lu-FAP-2286. 8Ga-FAP-2286 is an imaging agent that targets a certain protein which has been found in certain tumors called Fibroblast activation protein (FAP). Imaging using 68Ga-FAP-2286 will determine if participants are eligible to receive the experimental radiotherapy, 177Lu-FAP-2286, which researchers think may kill cancer cells by delivering radiation to cancer cells that have fibroblast activation protein (FAP). Are you Eligible? (Inclusion Criteria) Have you been diagnosed with...
  • Principal Investigator:

    Ryan H. Moy, MD, PhD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this Study is to find out if an investigational drug, TYRA-430, is safe and effective at treating cancer in participants with locally advanced/metastatic liver cancer and other solid tumors tumors that have a certain mutation or alteration of a type of protein located on the surface of cancer cells. Investigational drug means that it has not been approved by the United States Food and Drug Administration (US FDA) to use or to treat any disease or cancer. This is the first time that the Study Drug has been used in people. Are you Eligible? (Inclusion Criteria) 18 years of age or...
  • Principal Investigator:

    Brian Henick, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...
  • Principal Investigator:

    Linda Y. Wu, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    The purpose of this study is to find the best dose of the study drug, BBO-11818, when used alone (single therapy) and in combination with other standard of care treatments, and to see what effects, good or bad, the study drug has on participants. While the standard of care treatments, pembrolizumab, pemetrexed, cisplatin, carboplatin, and cetuximab are FDA-approved individually, the combination of BBO-11818 with these treatments is considered experimental. The study drug, BBO-11818, has not been approved by the U.S. Food and Drug Administration (FDA). This is the first time that BBO- 11818...

Pages